Periodontal disease (PD) is more common in rheumatoid arthritis (RA), especially those with anti-citrullinated protein antibodies (ACPAs).  RA activity has been linked to the severity of PD and mucosal inflammation.

Acute low back pain (LBP) is a common cause of disability. An analysis in the Journal of Orthopaedic Research examined which non-opioid drugs are best for treating this condition.

Wang et al., in a JAMA Network Research Letter, recently reviewed Medicaid expenditures on adalimumab (ADA), sold under the brand name HUMIRA®. They noted that the introduction of the citrate-free formulation cost an extra $4.4B to Medicaid between 2014 and 2021.

The etiology of arthritis was studied using US National Health and Nutrition Examination Survey (NHANES) data and suggested that elevated concentrations of trace elements (TE: Pb, Cd, and Cu) were associated with increased risk of arthritis.